Optimizing Biomarker-Directed Therapy to Advance CRC Care: A Clinical Connections Session (Enduring from 72WC231)
CE Information
1.0 contact hour (0.56 pharmacology)Completion Time
1 hourAvailable Until
November 27, 2024Posted By
Prime CENavigate
Overview
Specialties
OncologySubspecialties
OncologyClinical Topics
OncologyIntended Audience: Medical and surgical oncologists in community and academic settings and their clinical teams of NPs, PAs, nurses, and pharmacists, as well as pathologists.
Novel and emerging biomarkers are improving outcomes for patients with colorectal cancer (CRC). Tune in for a comprehensive discussion on the latest advances in biomarker-directed therapy for CRC.
During this Clinical Connections webcast, multidisciplinary oncology experts discuss:
- Incorporating biomarker testing into treatment selection and sequencing
- The latest clinical efficacy and safety data of biomarker-driven combination therapies
- Coordinating multidisciplinary care
Be sure to download the Biomarker Testing Resource available as part of this program!
Learning Objectives
- Describe the established biomarkers and recommended biomarker tests for patients with colorectal cancer
- Evaluate evolving clinical data on the efficacy, safety, and utility of novel biomarker-driven combination therapies for the treatment of unresectable or metastatic colorectal cancer
- Apply biomarker testing results to guide treatment selection for patients with unresectable or metastatic colorectal cancer
- Assess potential logistical considerations for the incorporation of comprehensive colorectal cancer biomarker testing into clinical practice
Speakers
Antonia R. Sepulveda, MD, PhD
Professor & Chair, Department of Pathology
Ralph E. Lowe Professor in Oncology
George Washington University School of Medicine and Health Sciences
Chief of Pathology & Director of Clinical Laboratories
Associate Professor of Pathology and Laboratory Medicine
Robert Larner, MD College of Medicine
University of Vermont
Medical Director, Genomic Medicine
University of Vermont Medical Center
Burlington, VT
Zangmeister Cancer Center, American Oncology Network
CE Information
This activity offers 1.0 contact hour (0.56 pharmacology) to attendees.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.56 hour of pharmacology).
Disclosures
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
-
Nikoletta Sidiropoulos, MD (Speaker)
Advisory Board or Panel – Bayer, Genentech, Merck, PierianDxThe relationships reported above are related to the following therapeutic area: Oncology
Consultant – Bayer, Genentech, PierianDx -
Sameh Mikhail, MD (Speaker)
Advisory Board or Panel – IpsenThe relationships reported above are related to the following therapeutic area: Solid Tumor
Consultant – Ipsen
Speakers Bureau or other Promotional Education – Ipsen
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Antonia Sepulveda, MD (Speaker)
- Abimbola Farinde, PhD, PharmD (Reviewer)
- Richa Bhattarai, MD (Planner)
- Lisa Wakefield, MSN, APRN, FNP-BC (Planner)
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity